STIM Neuronetics
- 2.000
- +0.110+5.82%
Neuronetics News
California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults
MALVERN, Pa., July 11, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
Express News | Bluecross Blueshield Mi and Cambia Health Solutions Expand Tms Access for Depressed Adolescents
Express News | Neuronetics Announces BCBS of Michigan And Cambia Health Solutions To Broaden Access To NeuroStar TMS For Patients 15 And Older; Policy Updates Follow FDA Clearance For Adolescents With MDD
Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch
NeuroStar Launches Better Me Provider Program Nationwide
MALVERN, Pa., July 01, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting
MALVERN, Pa., June 13, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
Neuronetics And 3 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed higher by around 80 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders
Director Robert Cascella Acquires 50,000 Shares of Neuronetics Inc (STIM)
Neuronetics(STIM.US) Director Buys US$102.55K in Common Stock
$Neuronetics(STIM.US)$ Director CASCELLA ROBERT purchased 50,000 shares of common stock on Jun 6, 2024 at an average price of $2.051 for a total value of $102.55K.Source: Announcement What is statemen
Neuronetics to Present at the William Blair 44th Annual Growth Stock Conference
MALVERN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
Express News | Neuronetics Announced That Humana Has Become The First Commercial Payer To Address TMS Therapy Coverage For Adolescents
Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
Neuronetics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 — William Blair Upgrades Market Perform → Outperform 03/06/2024 207.69% Piper Sandler $7 → $8
Express News | Neuronetics Inc : William Blair Raises to Outperform Rating
Strong Buy Rating for Neuronetics Backed by Solid Financials and Growth Prospects
Take Care Before Jumping Onto Neuronetics, Inc. (NASDAQ:STIM) Even Though It's 36% Cheaper
Neuronetics, Inc. (NASDAQ:STIM) shareholders won't be pleased to see that the share price has had a very rough month, dropping 36% and undoing the prior period's positive performance. The recent dr
Buy Rating on Neuronetics: Solid Fundamentals and Growth Despite Challenges
Neuronetics, Inc. (STIM) Q1 2024 Earnings Call Transcript
Thank you for standing by. Welcome to the Neuronetics First Quarter 2024 Conference Call. At this time all participants are in a listen-only mode. After the speakers’ presentation there will be a question-and-answer session. [Operator Instructions]. Please be advised that today's conference call is being recorded.
Neuronetics | 10-Q: Quarterly report
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Beyond, Inc. (NYSE:BYON) fell sharply during Tuesday's session following weaker-than-expected quarterly results.Beyond posted adjusted loss of $1.22 per share, versus estimates for a loss of
Analysis
Price Target
No Data
